Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.Founded in 2002, Alnylam Pharmaceuticals is an established company that loves to hire graduates from Northeastern University, with 23.7% of its employees having attended Northeastern University. Alnylam Pharmaceuticals has established itself as a great place to work in Massachusetts, and it is number 7 on Zippia's list of Best Companies to Work for in Cambridge, MA.The average employee at Alnylam Pharmaceuticals makes $81,014 per year. Pay at Alnylam Pharmaceuticals is significantly lower than some of its highest paying competitors, like Gilead Sciences, Acorda Therapeutics, and Vertex Pharmaceuticals, which pay $99,828, $97,279, and $95,952, respectively.Based in Cambridge, MA, Alnylam Pharmaceuticals is a key player in the pharmaceutical industry with 1,323 employees and an annual revenue of $2.2B.
Alnylam Pharmaceuticals's mission statement
Build an independent, top-tier biopharmaceutical company founded on RNAi.
In demand companies are hiring! Let Zippi apply for you!
3.0/5
Alnylam Pharmaceuticals employee reviews
Based on 1 ratings
Do you work at Alnylam Pharmaceuticals?
Help job seekers learn about working at Alnylam Pharmaceuticals
The founders of Alnylam Pharmaceuticals are Amy W. Schulman, Phillip A. Sharp, John K. Clarke, David Bartel, Paul Schimmel, Phillip Zamore, Robert Langer and Thomas Tuschl.
The key people at Alnylam Pharmaceuticals are Yvonne L. Greenstreet, Amy W. Schulman and Phillip A. Sharp.
Key people
Yvonne L. Greenstreet
Amy W. Schulman
Phillip A. Sharp
John K. Clarke
David Bartel
Paul Schimmel
Phillip Zamore
Robert Langer
Thomas Tuschl
Alnylam Pharmaceuticals rankings
Alnylam Pharmaceuticals is ranked #62 on the Best Pharmaceutical companies to work for in America list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.
Rate the fairness of Alnylam Pharmaceuticals' compensation policies.
Alnylam Pharmaceuticals diversity
9.1
Diversity score
We calculated Alnylam Pharmaceuticals’s diversity score by measuring multiple factors, including the ethnic background, gender identity, and language skills of Alnylam Pharmaceuticals’s workforce.
Alnylam Pharmaceuticals diversity summary. Zippia estimates Alnylam Pharmaceuticals's demographics and statistics using a database of 30 million profiles. Zippia verifies estimates with BLS, Census, and current job openings data for accuracy. We calculated Alnylam Pharmaceuticals's diversity score by measuring multiple factors, including the ethnic background, gender identity, and language skills of Alnylam Pharmaceuticals's workforce.
Alnylam Pharmaceuticals has 1,323 employees.
51% of Alnylam Pharmaceuticals employees are women, while 49% are men.
The most common ethnicity at Alnylam Pharmaceuticals is White (59%).
16% of Alnylam Pharmaceuticals employees are Asian.
14% of Alnylam Pharmaceuticals employees are Hispanic or Latino.
The average employee at Alnylam Pharmaceuticals makes $81,014 per year.
Alnylam Pharmaceuticals employees are most likely to be members of the democratic party.
Employees at Alnylam Pharmaceuticals stay with the company for 4.2 years on average.
Do you work at Alnylam Pharmaceuticals?
Is Alnylam Pharmaceuticals' workforce diverse and inclusive?
Alnylam Pharmaceuticals financial performance
9.8
Performance score
We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.
Alnylam Pharmaceuticals currently has 1.0B in revenue. Alnylam Pharmaceuticals's most recent quarter produced 750.5m (q3'2023).
Compare Alnylam Pharmaceuticals salaries to competitors, including Gilead Sciences, Acorda Therapeutics, and Vertex Pharmaceuticals. Employees at Gilead Sciences earn the highest average yearly salary of $99,828. The salaries at Acorda Therapeutics average $97,279 per year, and the salaries at Vertex Pharmaceuticals come in at $95,952 per year.
Rank
Company
Average salary
Jobs
1
$99,828
0
2
$97,279
0
3
$95,952
0
4
$94,985
0
5
$93,886
0
6
$92,986
0
7
$91,901
0
8
$90,328
0
9
$90,170
0
10
$85,589
0
Show more
Are you an executive, HR leader, or brand manager at Alnylam Pharmaceuticals?
Claiming and updating your company profile on Zippia is free and easy.
Alnylam Pharmaceuticals FAQs
When was Alnylam Pharmaceuticals founded?
How many employees does Alnylam Pharmaceuticals have?
Zippia gives an in-depth look into the details of Alnylam Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alnylam Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alnylam Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alnylam Pharmaceuticals. The data presented on this page does not represent the view of Alnylam Pharmaceuticals and its employees or that of Zippia.
Alnylam Pharmaceuticals may also be known as or be related to Alnylam Pharmaceuticals, Alnylam Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc. and Alnylam Pharmaceuticals, Inc.